HER3-Dxd has been evaluated in the phase II HERTHENA-Lung01 (NCT04619004) trial in participants with metastatic or locally advanced NSCLC with canonical activating EGFR mutations (exon 19 deletion or L858R) who have received and progressed on or after at least one EGFR TKI and one platinum-based chemotherapy-containing regimen. Here, ERBB3 is linked to non-small cell lung carcinoma.